Baseline characteristics for PsA patients with or without detectable antidrug antibodies
| Total number of (patients n=103) | Patients without detectable antidrug antibodies (n=80) | Patients with detectable antidrug antibodies (n=23) | |
|---|---|---|---|
| Demographics | |||
| Male, number (%) | 55 (53) | 44 (55) | 11 (48) |
| Age years, mean (SD) | 50 (12) | 50 (11) | 50 (14) |
| BMI, mean (SD) | 28 (5.4) | 28 (5.1)* | 31 (5.8)* |
| Smoking, number (%) | 25 (25) | 21 (26) | 4 (17) |
| DMARD therapy | |||
| Prior DMARDs, median (IQR) | 2 (1–2) | 2 (1–2) | 2 (1–3) |
| Prior biological, number (%) | 26 (24) | 19 (24) | 7 (30) |
| Prior etanercept, number (%) | 23 (22) | 17 (21) | 6 (26) |
| DMARD use, number (%) | 87 (85) | 75 (94)* | 12 (52)* |
| MTX use, number (%) | 80 (78) | 70 (88)* | 10 (44)* |
| MTX dose mg/week, median (IQR) | 20 (15–25) | 20 (14–25) | 17.5 (14–25) |
| Prednisone use, number (%) | 9 (9) | 9 (11) | –* |
| Prednisone dose mg/day, median (IQR) | 10 (2–11) | 10 (2–11) | –* |
| Disease status | |||
| Disease duration psoriasis yrs, median (IQR) | 10 (4–20) | 10 (3–21) | 9 (4–19) |
| Disease duration PsA yrs, median (IQR) | 6 (2–12) | 6 (2–12) | 7 (2–12) |
| DAS28, mean (SD) | 4.0 (1.2) | 4.1 (1.2) | 3.7 (1.2) |
| ESR mm/h, median (IQR) | 11 (4–21) | 11 (4–21) | 8 (5–27) |
| CRP mg/L, median (IQR) | 5 (2–9) | 4 (1–9) | 6 (2–9) |
| PASI, median (IQR) | 0.6 (0–2.4) | 0.6 (0–2.2) | 1.2 (0–2.8) |
| Tender joint count (72 joints), median (IQR) | 8 (3–17) | 9 (4–17) | 6 (2–19) |
| Swollen joint count (70 joints), median (IQR) | 6 (3–10) | 6 (3–10) | 5 (1–11) |
*There is a significant difference for: BMI; p=0.006, DMARD use; p<0.0001, MTX use; p<0.000, prednisone use and dosage; p<0.0001.
BMI, Body Mass Index; CRP, c reactive protein; DAS28, 28 joint disease activity score; DMARD, disease modifying antirheumatic drugs; ESR, Erythrocyte Sedimentation Rate; MTX, methotrexate; PASI, Psoriasis Area Severity Index.